ArticlePharmaceutical research2026
Enabling Personalized Dose Formulation by Evaporative Crystallization Process.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeEvaluating a solution-based drug impregnation strategy for individualized dose formulation of warfarin sodium isopropanol (WS-IPA), a drug with a narrow therapeutic index, using microcrystalline cellulose (MCC) placebo tablets as porous carrier.
methodsTwo formulation strategies were investigated: Add dissolved WS-IPA dropwise to a tablet, followed by solvent evaporation (M1) and dropwise addition coupled with antisolvent crystallization (M2). The tablets were characterized using powder X-ray diffraction and Raman spectroscopy for solid-form assessment. Scanning electron microscopy with energy-dispersive spectroscopy was used to visualize drug distribution and morphology. Principal component analysis was applied for Raman spectra to identify spectral differences and developed partial least squares (PLS) regression to determine WS-IPA content.
resultsM1 resulted in amorphous WS-IPA under the conditions studied. In contrast, the antisolvent crystallization strategy (M2) promoted the formation of crystalline WS-IPA within the MCC tablets. The M2 tablets met USP dissolution requirements similar to commercial tablets (Coumadin®). External Raman PLS model validation demonstrated the potential for non-destructive WS-IPA content estimation across individualized doses, with a Root Mean Square Error of Prediction of 0.35 mg.
conclusionM2 with Raman-based process analytical technology enabled crystallization control and non-destructive tablet analysis for the flexible production of individualized solid dosage forms of WS-IPA.
Indexed as
Identifiers
42426414What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.